董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Olivia C. Ware | 女 | Director | 65 | 未披露 | 未持股 | 2022-03-31 |
| 乐霄 | 男 | Director | 33 | 未披露 | 未持股 | 2022-03-31 |
| Xiaowei Chang | 男 | Director | 39 | 未披露 | 未持股 | 2022-03-31 |
| Katrin Rupalla | 女 | Director | 54 | 未披露 | 未持股 | 2022-03-31 |
| Feng Tian | 男 | President, Chief Executive Officer and Chairman of the Board | 54 | 未披露 | 未持股 | 2022-03-31 |
| Paul Maier | 男 | Director | 74 | 未披露 | 未持股 | 2022-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sonja Nelson | 女 | Chief Financial Officer | 49 | 未披露 | 未持股 | 2022-03-31 |
| Feng Tian | 男 | President, Chief Executive Officer and Chairman of the Board | 54 | 未披露 | 未持股 | 2022-03-31 |
董事简历
中英对照 | 中文 | 英文- Olivia C. Ware
-
Olivia C.Ware自2021年3月起担任公司董事。Ware女士在药物开发、商业化和梦百合管理方面有着20多年的经验。从2019年11月到2021年3月，Ware女士担任赛诺菲（Sanofi S.A.）于2020年收购的Principia BiopharmaInc.（BTK）的高级副总裁，BTK专营权负责人，负责为该公司的三个BTKI分子制定总体投资组合战略。从2018年到2019年，Ware女士担任Proteus Digital Health，Inc.美国市场和特许经营开发高级副总裁，。2011年至2018年，Ware女士曾在多家公共和私人生物制药公司担任私人顾问。2016年至2017年，Ware女士担任Cytrx，Inc.的首席商务官。从1997年到2010年，Ware女士在Genentech，Inc.担任各种职务，在商业，团队领导和产品开发方面的责任越来越大。在Genentech任职期间，Ware女士在几种商业药物产品的推出中发挥了关键作用，包括Rituxan®；，Herceptin®；，Avastin®；和Lucentis®；，并担任肿瘤学团队领导负责分子，疾病和平台战略计划以及肿瘤学投资组合管理。Ware女士拥有戴维森学院（Davidson College）心理学学士学位和北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）金融与营销工商管理硕士学位。
Olivia C. Ware has served on Ambrx Biopharma Inc. board of directors since April 2021. Ms. Ware has more than 20 years of experience in pharmaceutical drug development, commercialization and healthcare management. Ms. Ware has served as a director at Revance Therapeutics, Inc. since March 2021. From November 2019 to March 2021, Ms. Ware served as the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., which was acquired by Sanofi S.A. in 2020, where she was responsible for developing overall portfolio strategy for the company's three BTKi molecules. From August 2018 to November 2019, Ms. Ware served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc. From January 2010 to August 2018, Ms. Ware worked in a number of public and private biopharma firms as a private consultant. From January 2016 to September 2016, Ms. Ware was the Chief Commercial Officer at CytRx, Inc. From 1997 to 2010, Ms. Ware worked at Genentech, Inc. in a variety of roles of increasing responsibility in commercial, team leadership and product development. During her time at Genentech, Ms. Ware played a key role in the launch of several commercial drug products, including Rituxan, Herceptin Avastin and Lucentis, and as Head of Oncology Team Leadership was responsible for molecule, disease and platform strategic plans and oncology portfolio management. Ms. Ware holds an A.B. in Psychology from Davidson College and an M.B.A. in Finance and Marketing from the University of North Carolina at Chapel Hill. - Olivia C.Ware自2021年3月起担任公司董事。Ware女士在药物开发、商业化和梦百合管理方面有着20多年的经验。从2019年11月到2021年3月，Ware女士担任赛诺菲（Sanofi S.A.）于2020年收购的Principia BiopharmaInc.（BTK）的高级副总裁，BTK专营权负责人，负责为该公司的三个BTKI分子制定总体投资组合战略。从2018年到2019年，Ware女士担任Proteus Digital Health，Inc.美国市场和特许经营开发高级副总裁，。2011年至2018年，Ware女士曾在多家公共和私人生物制药公司担任私人顾问。2016年至2017年，Ware女士担任Cytrx，Inc.的首席商务官。从1997年到2010年，Ware女士在Genentech，Inc.担任各种职务，在商业，团队领导和产品开发方面的责任越来越大。在Genentech任职期间，Ware女士在几种商业药物产品的推出中发挥了关键作用，包括Rituxan®；，Herceptin®；，Avastin®；和Lucentis®；，并担任肿瘤学团队领导负责分子，疾病和平台战略计划以及肿瘤学投资组合管理。Ware女士拥有戴维森学院（Davidson College）心理学学士学位和北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）金融与营销工商管理硕士学位。
- Olivia C. Ware has served on Ambrx Biopharma Inc. board of directors since April 2021. Ms. Ware has more than 20 years of experience in pharmaceutical drug development, commercialization and healthcare management. Ms. Ware has served as a director at Revance Therapeutics, Inc. since March 2021. From November 2019 to March 2021, Ms. Ware served as the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., which was acquired by Sanofi S.A. in 2020, where she was responsible for developing overall portfolio strategy for the company's three BTKi molecules. From August 2018 to November 2019, Ms. Ware served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc. From January 2010 to August 2018, Ms. Ware worked in a number of public and private biopharma firms as a private consultant. From January 2016 to September 2016, Ms. Ware was the Chief Commercial Officer at CytRx, Inc. From 1997 to 2010, Ms. Ware worked at Genentech, Inc. in a variety of roles of increasing responsibility in commercial, team leadership and product development. During her time at Genentech, Ms. Ware played a key role in the launch of several commercial drug products, including Rituxan, Herceptin Avastin and Lucentis, and as Head of Oncology Team Leadership was responsible for molecule, disease and platform strategic plans and oncology portfolio management. Ms. Ware holds an A.B. in Psychology from Davidson College and an M.B.A. in Finance and Marketing from the University of North Carolina at Chapel Hill.
- 乐霄
-
乐霄先生，于2020年12月获委任为北海康成制药有限公司董事，并于2021年6月21日调任非执行董事。乐先生负责参与制定公司的企业及业务战略。乐先生自2020年11月起担任Ambrx Biopharma Inc.（纽约证券交易所：AMAM）的非执行董事，并担任无锡药明康德（香港交易所：2359）的企业发展和投资部投资总监。在此之前，乐先生自2016年5月起在6Dimensions Capital（前称为Frontline Bio Ventures，一家主要业务为股权投资的公司）担任投资专家。乐先生于2013年5月获得约翰霍普金斯大学化学及生物分子工程学士学位，并于2015年6月获得麻省理工学院金融硕士学位。
Xiao Le has served on Ambrx Biopharma Inc. board of directors since November 2020. Mr. Le is currently a director of Corporate Development and Investment at WuXi Apptec (WuXi), where he joined in 2019. Prior to WuXi, Mr. Le served at 6 Dimensions Capital (previously named Frontline BioVentures), an investment company, as an investment professional since 2014. Mr. Le holds a B.S. in chemical and biomolecular engineering from Johns Hopkins University, and a masters of finance from the Massachusetts Institute of Technology. - 乐霄先生，于2020年12月获委任为北海康成制药有限公司董事，并于2021年6月21日调任非执行董事。乐先生负责参与制定公司的企业及业务战略。乐先生自2020年11月起担任Ambrx Biopharma Inc.（纽约证券交易所：AMAM）的非执行董事，并担任无锡药明康德（香港交易所：2359）的企业发展和投资部投资总监。在此之前，乐先生自2016年5月起在6Dimensions Capital（前称为Frontline Bio Ventures，一家主要业务为股权投资的公司）担任投资专家。乐先生于2013年5月获得约翰霍普金斯大学化学及生物分子工程学士学位，并于2015年6月获得麻省理工学院金融硕士学位。
- Xiao Le has served on Ambrx Biopharma Inc. board of directors since November 2020. Mr. Le is currently a director of Corporate Development and Investment at WuXi Apptec (WuXi), where he joined in 2019. Prior to WuXi, Mr. Le served at 6 Dimensions Capital (previously named Frontline BioVentures), an investment company, as an investment professional since 2014. Mr. Le holds a B.S. in chemical and biomolecular engineering from Johns Hopkins University, and a masters of finance from the Massachusetts Institute of Technology.
- Xiaowei Chang
-
常晓伟自2015年6月起担任我们的董事。Chang先生在医疗保健行业拥有超过14年的经验。Chang先生自2014年以来一直担任厚朴投资厚朴医疗保健投资团队的董事总经理，在那里他在构建厚朴医疗保健生态系统，交易采购和执行方面发挥着不可或缺的作用。在厚朴之前，常先生于2011年至2014年担任中金公司Corporation Private Equity（CICC）的高级合伙人，这是一家领先的中国私募股权公司。在加入CICC之前，Chang先生于2007年至2011年在Roland Berger战略顾问公司担任团队负责人。常先生毕业于清华大学，获得电气工程学士和硕士学位。他是CFA的特许持有人。
Xiaowei Chang has served on Ambrx Biopharma Inc. board of directors since June 2015. Mr. Chang has over 15 years of experience in the healthcare industry. Mr. Chang has served as a Managing Director of the Healthcare investment team at HOPU Investments (HOPU) since 2014, where he plays an integral role in building HOPU's healthcare ecosystem, deal sourcing and execution. Prior to HOPU, Mr. Chang was a senior associate at China International Capital Corporation Private Equity (CICC), a leading China-based private equity firm from 2011 to 2014. Prior to CICC, Mr. Chang worked for Roland Berger Strategy Consultants as a team leader from 2007 to 2011. Mr. Chang graduated from Tsinghua University with a B.S. and a M.S. in Electrical Engineering. He is a C.F.A. charter holder. - 常晓伟自2015年6月起担任我们的董事。Chang先生在医疗保健行业拥有超过14年的经验。Chang先生自2014年以来一直担任厚朴投资厚朴医疗保健投资团队的董事总经理，在那里他在构建厚朴医疗保健生态系统，交易采购和执行方面发挥着不可或缺的作用。在厚朴之前，常先生于2011年至2014年担任中金公司Corporation Private Equity（CICC）的高级合伙人，这是一家领先的中国私募股权公司。在加入CICC之前，Chang先生于2007年至2011年在Roland Berger战略顾问公司担任团队负责人。常先生毕业于清华大学，获得电气工程学士和硕士学位。他是CFA的特许持有人。
- Xiaowei Chang has served on Ambrx Biopharma Inc. board of directors since June 2015. Mr. Chang has over 15 years of experience in the healthcare industry. Mr. Chang has served as a Managing Director of the Healthcare investment team at HOPU Investments (HOPU) since 2014, where he plays an integral role in building HOPU's healthcare ecosystem, deal sourcing and execution. Prior to HOPU, Mr. Chang was a senior associate at China International Capital Corporation Private Equity (CICC), a leading China-based private equity firm from 2011 to 2014. Prior to CICC, Mr. Chang worked for Roland Berger Strategy Consultants as a team leader from 2007 to 2011. Mr. Chang graduated from Tsinghua University with a B.S. and a M.S. in Electrical Engineering. He is a C.F.A. charter holder.
- Katrin Rupalla
-
Katrin Rupalla自2021年4月起担任我们的董事。Rupalla博士自2020年9月以来一直在4Dpharma plc（一家公共生物治疗公司）的董事会任职，自2020年6月以来一直在Iqure Pharma（一家私人生物技术公司）的董事会任职。她目前担任Lundbeck的全球监管战略，研究与开发质量和医疗信息高级副总裁，自2019年10月以来一直在那里任职。在此之前，Rupalla博士于2018年4月至2019年9月担任Bristol-Myers Squibb的副总裁，肿瘤全球监管科学主管，副总裁，中国研究与开发主管（2016年6月至2018年9月）和欧盟监管科学副总裁（2012年至2015年）。Rupalla博士拥有理学硕士学位。Philipps-University Marburg药理学博士学位和CNS药理学博士学位，Jones International University项目管理工商管理硕士学位。
Katrin Rupalla has served on Ambrx Biopharma Inc. board of directors since in April 2021. Dr. Rupalla has more than 25 years' experience in the pharmaceutical industry at a global scale serving the United States, Europe and China. Since December 2021, Dr. Rupalla has served as Chief Executive Officer of Ymmunobio AG, a Swiss preclinical stage biotech company. She previously served as the Senior Vice President, Global Regulatory Strategy, Research and Development Quality and Medical Information at Lundbeck from October 2019 to November 2021. Prior to that, Dr. Rupalla served as Vice President, Head of Oncology Global Regulatory Sciences from April 2018 to September 2019, Vice President, China Head of Research and Development from June 2016 to September 2018, and Vice President, EU Regulatory Sciences from 2012 to 2015 at Bristol-Myers Squibb. Dr. Rupalla has served on the board of 4D Pharma plc, a public biotherapeutic company, since September 2020, and on the board of iQure Pharma, a private biotech company, since June 2020. Dr. Rupalla holds a M.Sc. in Pharmacy and a Ph.D. in CNS Pharmacology from the Philipps-University Marburg and an M.B.A. in Project Management from Jones International University. - Katrin Rupalla自2021年4月起担任我们的董事。Rupalla博士自2020年9月以来一直在4Dpharma plc（一家公共生物治疗公司）的董事会任职，自2020年6月以来一直在Iqure Pharma（一家私人生物技术公司）的董事会任职。她目前担任Lundbeck的全球监管战略，研究与开发质量和医疗信息高级副总裁，自2019年10月以来一直在那里任职。在此之前，Rupalla博士于2018年4月至2019年9月担任Bristol-Myers Squibb的副总裁，肿瘤全球监管科学主管，副总裁，中国研究与开发主管（2016年6月至2018年9月）和欧盟监管科学副总裁（2012年至2015年）。Rupalla博士拥有理学硕士学位。Philipps-University Marburg药理学博士学位和CNS药理学博士学位，Jones International University项目管理工商管理硕士学位。
- Katrin Rupalla has served on Ambrx Biopharma Inc. board of directors since in April 2021. Dr. Rupalla has more than 25 years' experience in the pharmaceutical industry at a global scale serving the United States, Europe and China. Since December 2021, Dr. Rupalla has served as Chief Executive Officer of Ymmunobio AG, a Swiss preclinical stage biotech company. She previously served as the Senior Vice President, Global Regulatory Strategy, Research and Development Quality and Medical Information at Lundbeck from October 2019 to November 2021. Prior to that, Dr. Rupalla served as Vice President, Head of Oncology Global Regulatory Sciences from April 2018 to September 2019, Vice President, China Head of Research and Development from June 2016 to September 2018, and Vice President, EU Regulatory Sciences from 2012 to 2015 at Bristol-Myers Squibb. Dr. Rupalla has served on the board of 4D Pharma plc, a public biotherapeutic company, since September 2020, and on the board of iQure Pharma, a private biotech company, since June 2020. Dr. Rupalla holds a M.Sc. in Pharmacy and a Ph.D. in CNS Pharmacology from the Philipps-University Marburg and an M.B.A. in Project Management from Jones International University.
- Feng Tian
-
Feng Tian自2018年7月起担任我们的董事，首席执行官兼总裁，包括自2020年11月起担任董事会主席。自2004年加入以来，他一直担任越来越重要的职务。此前，田博士于2015年至2018年担任首席科学官，负责监督我们的研究与开发。在加入AMBRX之前，田博士在斯克里普斯研究所（Scripps Research Institute）的PeterG.Schultz教授小组进行博士后研究，在那里他的工作涉及催化抗体，非天然氨基酸掺入和生物传感器。田博士在佛罗里达大学获得化学博士学位，并在William R.Dolbier教授的指导下撰写了物理有机化学领域的论文。他在北京大学获得化学学士学位。田博士是Luxvitae Therapeutics Inc.的联合创始人。
Feng Tian has served on Ambrx Biopharma Inc. board of directors and as Ambrx Biopharma Inc. Chief Executive Officer and President since July 2018, including as Chairman of the board of directors since November 2020. He has held positions of increasing responsibility since joining Ambrx Biopharma Inc. in 2004. Previously, as Ambrx Biopharma Inc. Chief Scientific Officer from 2015 to 2018, Dr. Tian oversaw Ambrx Biopharma Inc. research and development. Prior to joining Ambrx Biopharma Inc. , Dr. Tian conducted his post-doctoral studies at The Scripps Research Institute in Professor Peter G. Schultz's group, where his work involved catalytic antibodies, non-natural amino acid incorporation, and biosensors. Dr. Tian received his Ph.D. in Chemistry from the University of Florida, with a dissertation in the field of Physical Organic Chemistry, under the supervision of Professor William R. Dolbier, Jr. He received his B.S. in Chemistry from Peking University. Dr. Tian is a co-founder of LuxVitae Therapeutics Inc. - Feng Tian自2018年7月起担任我们的董事，首席执行官兼总裁，包括自2020年11月起担任董事会主席。自2004年加入以来，他一直担任越来越重要的职务。此前，田博士于2015年至2018年担任首席科学官，负责监督我们的研究与开发。在加入AMBRX之前，田博士在斯克里普斯研究所（Scripps Research Institute）的PeterG.Schultz教授小组进行博士后研究，在那里他的工作涉及催化抗体，非天然氨基酸掺入和生物传感器。田博士在佛罗里达大学获得化学博士学位，并在William R.Dolbier教授的指导下撰写了物理有机化学领域的论文。他在北京大学获得化学学士学位。田博士是Luxvitae Therapeutics Inc.的联合创始人。
- Feng Tian has served on Ambrx Biopharma Inc. board of directors and as Ambrx Biopharma Inc. Chief Executive Officer and President since July 2018, including as Chairman of the board of directors since November 2020. He has held positions of increasing responsibility since joining Ambrx Biopharma Inc. in 2004. Previously, as Ambrx Biopharma Inc. Chief Scientific Officer from 2015 to 2018, Dr. Tian oversaw Ambrx Biopharma Inc. research and development. Prior to joining Ambrx Biopharma Inc. , Dr. Tian conducted his post-doctoral studies at The Scripps Research Institute in Professor Peter G. Schultz's group, where his work involved catalytic antibodies, non-natural amino acid incorporation, and biosensors. Dr. Tian received his Ph.D. in Chemistry from the University of Florida, with a dissertation in the field of Physical Organic Chemistry, under the supervision of Professor William R. Dolbier, Jr. He received his B.S. in Chemistry from Peking University. Dr. Tian is a co-founder of LuxVitae Therapeutics Inc.
- Paul Maier
-
Paul Maier自2022年2月起在Ambrx Biopharma董事会任职。他是一位经验丰富的高管，拥有丰富的高级运营、国际和财务管理经验，包括在快速增长的制药和生物技术公司工作了25年。Maier先生2009年至2014年担任Sequenom, Inc.首席财务官。在加入Sequenom之前，他在Ligand制药工作了15年，曾担任高级副总裁、首席财务官。在其职业生涯的早期，Maier先生曾在DFS West和ICN Pharmaceuticals，Inc.等公司以及其他几家私营公司担任过各种财务主管职务。Maier先生目前在Small Pharma Inc.、4D Pharma PLC、Eton Pharmaceuticals和国际干细胞公司的董事会任职。Maier先生在宾夕法尼亚州立大学获得商业物流学士学位，并在哈佛商学院获得工商管理硕士学位。
Paul Maier has served on Ambrx Biopharma Inc. board of directors since February 2022. He is a seasoned executive with extensive senior operational, international, and financial management experience, including 25 years in rapid growth pharmaceutical and biotechnology companies. Mr. Maier was Chief Financial Officer of Sequenom, Inc., from 2009 until 2014. Prior to Sequenom, he spent 15 years at Ligand Pharmaceuticals where he served as the Senior Vice President, Chief Financial Officer. Early in his career, Mr. Maier held various financial executive roles at companies such as DFS West and ICN Pharmaceuticals, Inc., and several other private companies. Mr. Maier currently serves on the Board of Directors for Small Pharma Inc., 4D Pharma PLC, Eton Pharmaceuticals, and International Stem Cell Corporation. Mr. Maier received his B.S. in Business Logistics from Pennsylvania State University and received his M.B.A. from Harvard Graduate School of Business. - Paul Maier自2022年2月起在Ambrx Biopharma董事会任职。他是一位经验丰富的高管，拥有丰富的高级运营、国际和财务管理经验，包括在快速增长的制药和生物技术公司工作了25年。Maier先生2009年至2014年担任Sequenom, Inc.首席财务官。在加入Sequenom之前，他在Ligand制药工作了15年，曾担任高级副总裁、首席财务官。在其职业生涯的早期，Maier先生曾在DFS West和ICN Pharmaceuticals，Inc.等公司以及其他几家私营公司担任过各种财务主管职务。Maier先生目前在Small Pharma Inc.、4D Pharma PLC、Eton Pharmaceuticals和国际干细胞公司的董事会任职。Maier先生在宾夕法尼亚州立大学获得商业物流学士学位，并在哈佛商学院获得工商管理硕士学位。
- Paul Maier has served on Ambrx Biopharma Inc. board of directors since February 2022. He is a seasoned executive with extensive senior operational, international, and financial management experience, including 25 years in rapid growth pharmaceutical and biotechnology companies. Mr. Maier was Chief Financial Officer of Sequenom, Inc., from 2009 until 2014. Prior to Sequenom, he spent 15 years at Ligand Pharmaceuticals where he served as the Senior Vice President, Chief Financial Officer. Early in his career, Mr. Maier held various financial executive roles at companies such as DFS West and ICN Pharmaceuticals, Inc., and several other private companies. Mr. Maier currently serves on the Board of Directors for Small Pharma Inc., 4D Pharma PLC, Eton Pharmaceuticals, and International Stem Cell Corporation. Mr. Maier received his B.S. in Business Logistics from Pennsylvania State University and received his M.B.A. from Harvard Graduate School of Business.
高管简历
中英对照 | 中文 | 英文- Sonja Nelson
Sonja Nelson于2016年5月被任命为我们的首席会计官，并自2015年11月起担任我们的副总裁兼公司财务总监。在加入该公司之前，纳尔逊女士曾担任分子诊断公司Altheadx，Inc.的Vice President兼公司财务总监，并于2014年7月至2015年10月受聘为该公司IPO做准备。此前，纳尔逊女士曾于2012年5月至2014年6月担任CadencePharmaceuticals，Inc.的高级董事兼财务总监。在此之前，Nelson从2008年9月到2012年5月担任Cricket Communications，Inc.（一家价值30亿美元的无线服务提供商）总会计主管。Nelson女士在毕马威会计师事务所（KPMG LLP）开始她的职业生涯，持有德国普福尔茨海姆应用科学大学（University of Applied Sciences）会计和税收学士学位，是一名注册会计师。
Sonja Nelson,has served on Motus Gi Holdings, Inc. Board since June 2021. In June 2021, Ms. Nelson began serving as the Chief Financial Officer of Ambrx Biopharma, Inc, (NASDAQ: AMAM). Prior to that, Ms. Nelson, served as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX), from March 2021 to June 2021. Ms. Nelson served as the Chief Financial Officer of NantKwest, Inc. from June 2018 to March 2021, at which time NantKwest, Inc. merged with ImmunityBio, Inc. (NASDAQ: IBRX). Ms. Nelson previously served as the Chief Accounting Officer of NantKwest, Inc. from May 2016 to June 2018 and as the VP/Corporate Controller of NantKwest, Inc. from November 2015 to May 2016. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc., now merged with ImmunityBio, Inc. (NASDAQ: IBRX)) from October 2017 to June 2021. Prior to joining NantKwest, Inc., Ms. Nelson was Vice President and Corporate Controller at AltheaDx, Inc. from July 2014 through October 2015. Previously, Ms. Nelson was Senior Director and Controller at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc) from May 2012 through June 2014. Prior to that, Ms. Nelson was Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T, Inc.) from September 2008 through May 2012. Ms. Nelson began her career with KPMG LLP, holds a Bachelor's degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany, and is a Certified Public Accountant.- Sonja Nelson于2016年5月被任命为我们的首席会计官，并自2015年11月起担任我们的副总裁兼公司财务总监。在加入该公司之前，纳尔逊女士曾担任分子诊断公司Altheadx，Inc.的Vice President兼公司财务总监，并于2014年7月至2015年10月受聘为该公司IPO做准备。此前，纳尔逊女士曾于2012年5月至2014年6月担任CadencePharmaceuticals，Inc.的高级董事兼财务总监。在此之前，Nelson从2008年9月到2012年5月担任Cricket Communications，Inc.（一家价值30亿美元的无线服务提供商）总会计主管。Nelson女士在毕马威会计师事务所（KPMG LLP）开始她的职业生涯，持有德国普福尔茨海姆应用科学大学（University of Applied Sciences）会计和税收学士学位，是一名注册会计师。
- Sonja Nelson,has served on Motus Gi Holdings, Inc. Board since June 2021. In June 2021, Ms. Nelson began serving as the Chief Financial Officer of Ambrx Biopharma, Inc, (NASDAQ: AMAM). Prior to that, Ms. Nelson, served as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX), from March 2021 to June 2021. Ms. Nelson served as the Chief Financial Officer of NantKwest, Inc. from June 2018 to March 2021, at which time NantKwest, Inc. merged with ImmunityBio, Inc. (NASDAQ: IBRX). Ms. Nelson previously served as the Chief Accounting Officer of NantKwest, Inc. from May 2016 to June 2018 and as the VP/Corporate Controller of NantKwest, Inc. from November 2015 to May 2016. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc., now merged with ImmunityBio, Inc. (NASDAQ: IBRX)) from October 2017 to June 2021. Prior to joining NantKwest, Inc., Ms. Nelson was Vice President and Corporate Controller at AltheaDx, Inc. from July 2014 through October 2015. Previously, Ms. Nelson was Senior Director and Controller at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc) from May 2012 through June 2014. Prior to that, Ms. Nelson was Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T, Inc.) from September 2008 through May 2012. Ms. Nelson began her career with KPMG LLP, holds a Bachelor's degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany, and is a Certified Public Accountant.
- Feng Tian
Feng Tian自2018年7月起担任我们的董事，首席执行官兼总裁，包括自2020年11月起担任董事会主席。自2004年加入以来，他一直担任越来越重要的职务。此前，田博士于2015年至2018年担任首席科学官，负责监督我们的研究与开发。在加入AMBRX之前，田博士在斯克里普斯研究所（Scripps Research Institute）的PeterG.Schultz教授小组进行博士后研究，在那里他的工作涉及催化抗体，非天然氨基酸掺入和生物传感器。田博士在佛罗里达大学获得化学博士学位，并在William R.Dolbier教授的指导下撰写了物理有机化学领域的论文。他在北京大学获得化学学士学位。田博士是Luxvitae Therapeutics Inc.的联合创始人。
Feng Tian has served on Ambrx Biopharma Inc. board of directors and as Ambrx Biopharma Inc. Chief Executive Officer and President since July 2018, including as Chairman of the board of directors since November 2020. He has held positions of increasing responsibility since joining Ambrx Biopharma Inc. in 2004. Previously, as Ambrx Biopharma Inc. Chief Scientific Officer from 2015 to 2018, Dr. Tian oversaw Ambrx Biopharma Inc. research and development. Prior to joining Ambrx Biopharma Inc. , Dr. Tian conducted his post-doctoral studies at The Scripps Research Institute in Professor Peter G. Schultz's group, where his work involved catalytic antibodies, non-natural amino acid incorporation, and biosensors. Dr. Tian received his Ph.D. in Chemistry from the University of Florida, with a dissertation in the field of Physical Organic Chemistry, under the supervision of Professor William R. Dolbier, Jr. He received his B.S. in Chemistry from Peking University. Dr. Tian is a co-founder of LuxVitae Therapeutics Inc.- Feng Tian自2018年7月起担任我们的董事，首席执行官兼总裁，包括自2020年11月起担任董事会主席。自2004年加入以来，他一直担任越来越重要的职务。此前，田博士于2015年至2018年担任首席科学官，负责监督我们的研究与开发。在加入AMBRX之前，田博士在斯克里普斯研究所（Scripps Research Institute）的PeterG.Schultz教授小组进行博士后研究，在那里他的工作涉及催化抗体，非天然氨基酸掺入和生物传感器。田博士在佛罗里达大学获得化学博士学位，并在William R.Dolbier教授的指导下撰写了物理有机化学领域的论文。他在北京大学获得化学学士学位。田博士是Luxvitae Therapeutics Inc.的联合创始人。
- Feng Tian has served on Ambrx Biopharma Inc. board of directors and as Ambrx Biopharma Inc. Chief Executive Officer and President since July 2018, including as Chairman of the board of directors since November 2020. He has held positions of increasing responsibility since joining Ambrx Biopharma Inc. in 2004. Previously, as Ambrx Biopharma Inc. Chief Scientific Officer from 2015 to 2018, Dr. Tian oversaw Ambrx Biopharma Inc. research and development. Prior to joining Ambrx Biopharma Inc. , Dr. Tian conducted his post-doctoral studies at The Scripps Research Institute in Professor Peter G. Schultz's group, where his work involved catalytic antibodies, non-natural amino acid incorporation, and biosensors. Dr. Tian received his Ph.D. in Chemistry from the University of Florida, with a dissertation in the field of Physical Organic Chemistry, under the supervision of Professor William R. Dolbier, Jr. He received his B.S. in Chemistry from Peking University. Dr. Tian is a co-founder of LuxVitae Therapeutics Inc.